- Total revenues of $13.0 million
- Non-GAAP net income from continuing operations of $2.5 million, or $0.12 per diluted share
- Net income of $2.0 million, or $0.09 per diluted share
Trade-Ideas LLC identified Ligand Pharmaceuticals (LGND) as a weak on high relative volume candidate
Here are Friday's top research calls, including downgrades for FireEye and Teva Pharmaceuticals, and upgrades for Kraft Heinz and U.S. Steel.
Trade-Ideas LLC identified Ligand Pharmaceuticals (LGND) as a "perilous reversal" (up big yesterday but down big today) candidate
Shares of SAGE Therapeutics jumped after the company reported data from its SAGE-547 clinical trial for the treatment of severe postpartum depression.